Abstract

Globus Medical will report fiscal second-quarter 2026 results on August 06, 2026 Post Market; this preview compiles market forecasts for revenue, margin, net income, and adjusted EPS with recent performance drivers and analyst sentiment since January 01, 2026.

Market Forecast

Based on current quarter estimates, Globus Medical is projected to deliver revenue of 782.84 million US dollars, with EBIT of 188.48 million and adjusted EPS of 1.10; year-over-year growth is expected at 5.53% for revenue, 41.04% for EBIT, and 45.51% for adjusted EPS. The company’s guidance framework and consensus imply margin expansion driven by operating leverage, with a focus on elevating profitability alongside mid-single-digit revenue growth. Main business momentum is expected to center on core musculoskeletal implant systems and enabling technologies, supported by continued integration efficiencies and salesforce execution. The most promising segment is enabling technologies, which, while smaller by revenue, continues to scale from a lower base and benefits from procedure growth and differentiated robotics/navigation offerings.

Last Quarter Review

In the previous reported quarter, Globus Medical posted revenue of 759.85 million US dollars, a gross profit margin of 69.20%, GAAP net profit attributable to shareholders of 124.00 million US dollars, a net profit margin of 16.36%, and adjusted EPS of 1.12, with revenue up 27.04% year over year and adjusted EPS up 64.71% year over year. A notable highlight was EBIT of 192.88 million, which exceeded market expectations and reflected integration synergies and disciplined expense control. By business line, revenue was led by musculoskeletal products at 732.98 million US dollars and enabling technologies at 26.87 million, with the core musculoskeletal portfolio representing the vast majority of sales; enabling technologies remains a smaller yet expanding contributor.

Current Quarter Outlook (with major analytical insights)

Core Musculoskeletal Portfolio

The core musculoskeletal implant systems, which generated 732.98 million US dollars last quarter, should remain the primary revenue driver this quarter. Demand trends across spine and trauma continue to be tied to overall procedure volumes, channel execution, and cadence of new product introductions. Given the mid-single-digit revenue growth outlook for the quarter, we expect stable to modestly improving unit volumes with price/mix broadly flat, while supply-chain conditions remain supportive relative to prior years. Operating leverage from salesforce productivity and integration efficiencies should help sustain the high-60s gross margin profile near the recent 69.20%, translating into better flow-through to EBIT. Key variables to watch are hospital capital budgets and scheduling dynamics, which could influence case volumes; however, the diversified implant suite and broader account penetration should buffer against localized volatility.

Enabling Technologies and Robotics/Navigation

Enabling technologies contributed 26.87 million US dollars last quarter and represent a structurally faster-growth vector given adoption curves in robotics and navigation. From a low base, the segment can outgrow the overall company, aided by placements, software utilization, and service revenues. Near-term revenue recognition depends on system placements and associated pull-through of disposables and upgrades; as backlogs normalize and install bases expand, recurring revenue density can improve. We anticipate the segment’s year-over-year trajectory to outpace the corporate average, supporting EBIT growth of 41.04% this quarter on consensus, as software-rich offerings typically carry higher gross margins and provide attractive incremental contribution. The main sensitivity is the lumpiness inherent in capital equipment cycles, but a broader ecosystem approach and integration with procedural workflows should smooth revenue cadence over time.

Profitability and EPS Drivers

Consensus implies a step-up in profitability with EBIT at 188.48 million US dollars and adjusted EPS at 1.10, reflecting 45.51% year-over-year EPS growth on just 5.53% revenue growth. This mix suggests continued operating leverage from integration synergies and disciplined spending. With last quarter’s net margin at 16.36% and gross margin at 69.20%, even modest revenue growth can yield substantial EPS expansion if overhead remains contained and mix tilts toward higher-margin technologies. Watch for progress on SG&A efficiency as well as manufacturing yields and logistics costs, which are key to maintaining gross margin at or above the high-60s level. Any updates on synergy capture and pipeline productivity could be the swing factors for sentiment around EPS durability into the back half of the year.

Analyst Opinions

Analyst commentary tracked since January 01, 2026 skews bullish, with the majority emphasizing continued EPS and EBIT outperformance potential relative to revenue growth. Several institutional notes highlight that last quarter’s 27.04% revenue growth and 64.71% adjusted EPS growth set a favorable comparison base, and the upcoming print could validate further margin gains as integration benefits accrue. Analysts also point to the rising contribution of enabling technologies as a positive mix shift that enhances profitability and competitive differentiation. While some caution that capital equipment timing can introduce near-term volatility, the prevailing view maintains that the company’s high-60s gross margin framework and focused execution support consensus EPS of 1.10 and EBIT of 188.48 million. The bullish camp expects steady case volume trends, stable pricing, and incremental adoption of navigation/robotics to underpin results, with upside risk if operating expenses come in lighter than anticipated.